BridgeMD
[68Ga]-FAPI PET/CT to visualize the activity of fibrogenic cells in patients with non-resolving shock lung.
EU CTIS ID: 2024-517257-27-00
What this study is testing
To relate pulmonary fibroblast activity in non-resolving ARDS patients, measured by FAPI-PET/CT, to 28 day mortality, ventilator-free days and alive at 28 days (VFD-28) and ICU length of stay.
- Phase III and phase IV (Integrated)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Adult (male >19 years of age and female >19 years of age) patients
- Mechanically ventilated
- Patiënt meets the criteria for non-resolving ARDS as at day 5 of the ARDS diagnosis one or more of the following criteria is true: 1. P/F ratio <200 mmHg 2. Positive End Expiratory Pressure (PEEP) at 12 cmH20 or more 3. Static lung compliance of < 50 ml/cmH20
- Deemed safe for transport by attending clinician (staff Intensivist)
- Informed consent signed by patiënt or legal representative
- For COVID-19 patients a SARS-CoV-2 PCR CT >30 is required
You likely can't join if
- Whomen who are pregnant or breastfeeding
- Inability to attain informed consent
- Too unstable for transport as judged by the treating staff intensivist
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.